A seemingly new topical treatment for rosacea is being trialled by Dow Pharmaceutical Sciences. The product is being evaluated firstly for the number of inflammatory lesions and global severity, and secondly for redness. This, along with the trial lasting 12 weeks, and the large size of the trial leads me to guess that IDP-115 is a metronidazole or azelaic acid variant.
Google hasn’t found any clues to IDP-115 or Dow Pharmaceutical Sciences. If you know anything more about this product, please leave a comment below.
From Clinical Trial NCT00667173
A Clinical Study Evaluating the Safety and Efficacy of IDP-115 in Patients With Rosacea. The purpose of this study is to assess the safety and effectiveness of IDP-115 in treating patients with rosacea.
3 comments ↓
Based on Dow Pharmaceutical Sciences corporate website, they are likely to conduct this study for another company.
Hi Alex,
It makes it even more mysterious that whoever has the new product is using an intermediate party to undertake the trial. Makes me think that it must be one of the existing big players – to be bothered with a trial of this size and outsourcing the logistics.
davidp.
I had a really bad, red,swollen nose at the weekend..the worst ever..As far as i know there are no over the counter products in the uk for us sufferers.There are so many strong medications and lotions that one can get at the chemist now…eg morning after pill….is there anything i could have bought?i find it annoying that i coulnt self help via the chemist…
Leave a Comment